Physician profile
Mark J Phelan
NPI 1801882030
$5,324.05
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $298 · 2021: $435 · 2022: $477 · 2023: $480 · 2024: $2,642 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,421 · Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,421.28 |
| Food and Beverage | $1,154.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,453.90 | 2023-2024 | Lumera 700 |
| Alcon Vision LLC | $672.43 | 2019-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Abbvie INC. | $400.56 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $303.06 | 2022-2025 | Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $296.84 | 2019-2021 | |
| Allergan, INC. | $198.83 | 2019-2022 | |
| Glaukos Corporation | $179.23 | 2019-2022 | |
| Sight Sciences, INC. | $145.70 | 2021-2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $95.50 | 2024-2025 | Xdemvy |
| Optos, INC. | $92.73 | 2021 | |
| Vantage Technology LLC | $68.71 | 2019-2022 | |
| Biotissue Holdings INC. | $67.91 | 2019 | |
| Rxsight INC | $63.40 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $62.77 | 2020-2021 | |
| Ocular Therapeutix, INC. | $40.91 | 2023-2024 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $34.26 | 2019-2021 | |
| Amgen INC. | $24.29 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $23.70 | 2021 | |
| Dompe US, INC. | $20.04 | 2025 | Oxervate |
| Eyepoint US, INC. | $18.55 | 2021 | |
| Rayner Intraocular Lenses Limited | $15.94 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Horizon Therapeutics Plc | $15.41 | 2023 | Tepezza |
| New World Medical,INC. | $15.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Phelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.